South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Earli is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Cyriac Roeding played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Earli

Earli’s mission is to make cancer a benign experience, by catching and curing it early. Earli is developing a radically new technique originally from Stanford University. Instead of searching, we force cancer cells to produce synthetic biomarkers that do not belong in the human body, which are then highly detectable and localizable in a PET scanner. We use biology for this, not chemistry, which allows for massive signal amplification. And the same technique also allows us to ultimately destroy the cancer.

To learn more about Earli, visit http://www.earli.com/

Contact:
Cyriac Roeding, Chief Executive Officer
650-250-4152
https://www.linkedin.com/in/cyriacroeding/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved